000756.SZ · 新华制药
China A-shares · RS rating 62 · As of 2026-10-14
| Price | 13.40 CNY |
|---|---|
| 1-day change | -3.8% |
| RS rating (overall / 1M / 3M / 12M) | 62 / 83 / 43 / 46 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 22 / 36 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +21.6% |
| Distance from 52-week high | +26.2% |
| Market cap (USD) | $1.5B |